within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XX78_Navitoclax;

model Navitoclax
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.34,
    Cl = 1.1388888888888888e-06,
    adminDuration = 600,
    adminMass = 150 / 1000000,
    adminCount = 1,
    Vd = 0.271,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.005666666666666667,
    Tlag = 36.0,
    Vdp = 0.344,
    k12 = 7.583333333333333e-06,
    k21 = 7.583333333333333e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Navitoclax</td></tr><tr><td>ATC code:</td><td>L01XX78</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>150</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>271</td><td>L</td></tr>
    <tr><td>clearance:</td><td>4.1</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Navitoclax is a small-molecule, orally bioavailable inhibitor of the anti-apoptotic Bcl-2 family of proteins, including Bcl-2, Bcl-xL, and Bcl-w. It is investigated as an anticancer agent due to its ability to induce apoptosis in cancer cells. It is not widely approved for clinical use and is mostly used in clinical trials for hematologic malignancies and some solid tumors.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with cancer following oral administration of navitoclax, single-dose and multiple-dose, in phase I clinical trials.</p><h4>References</h4><ol><li><p>Kaefer, A, et al., &amp; Xiong, H (2014). Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia. <i>Cancer chemotherapy and pharmacology</i> 74(3) 593–602. DOI:<a href=\"https://doi.org/10.1007/s00280-014-2530-9\">10.1007/s00280-014-2530-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25053389/\">https://pubmed.ncbi.nlm.nih.gov/25053389</a></p></li><li><p>King, AC, et al., &amp; Tang, LA (2017). Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies. <i>The Annals of pharmacotherapy</i> 51(5) 410–416. DOI:<a href=\"https://doi.org/10.1177/1060028016685803\">10.1177/1060028016685803</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28056525/\">https://pubmed.ncbi.nlm.nih.gov/28056525</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01XX78 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Navitoclax;
